logo

DermNet NZ

Ad

Authoritative facts about the skin from the New Zealand Dermatological Society Incorporated.

Ivermectin

Ivermectin is a macrocyclic lactone medicine used to treat parasitic infections. It is effective against infections with:

In New Zealand, Ivermectin is available in 3mg tablets (Stromectol™). The medicine is covered by Section 29 of the Medicines Act – which means it is not registered in New Zealand. It is available on prescription but full details of the prescription are required to be reported to the Minsitry of Health by the supplier.

Ivermectin has been used extensively as part of the World Health Organisation's Onchocerciasis Eradication Program. It has FDA approval for the treatment of strongyloides and onchocerciasis in the United States, other use is termed ‘off label’.

In treatment of scabies its use may be appropriate in selected cases where topical therapy is impractical or has failed and is particularly useful in cases of crusted scabies (also called ‘Norwegian’ scabies).

How does it work?

Ivermectin stimulates excessive release of neurotransmitters in the peripheral nervous system of parasites. It is thought to work by paralysing the parasite or inactivating the parasite gut. In humans the neurotransmitters acted on by ivermectin are in the brain. A protective barrier, called the blood-brain barrier, blocks ivermectin from reaching the human brain.

How is it taken?

Ivermectin is taken as a single dose with a glass of water. It is rapidly absorbed from the gut and metabolised in the liver.

Infestation Dose regime
Onchocerciasis Single dose of 150mcg/kg (may be repeated every 3 to 12 months)
Strongyloidiasis Single dose of 200mcg/kg
Scabies Dose of 200mcg/kg repeated in 7 to 14 days
Cutaneous larva migrans Single dose of 200mcg/kg

Side effects

Side effects are rare and usually minor. These include:

The safety of ivermectin in pregnant women has not been studied and such use is not recommended. Studies in animals have shown an increase in birth defects. Safety and effectiveness in children under 15kg has not been established. Ivermectin passes into breast milk and use during breast feeding is not recommended.

Drug interactions

No significant drug interactions are recognised.

Related information

On DermNet NZ:

References

Other websites:

Books about skin diseases:

See the DermNet NZ bookstore

Author: Dr Julie Smith MBChB FRACP, Dept of Dermatology Greenlane Hospital Auckland

DermNet does not provide an on-line consultation service.
If you have any concerns with your skin or its treatment, see a dermatologist for advice.